China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.
Deallus’ Chinese pharmaceutical market access model revolves around the following five aspects: company’s vision and objectives, drug discovery innovation, registration for approval, National Reimbursement Drug List (NRDL), Volume-based procurement (VBP) and pricing, Hospital Drug Listing (HDL) and physician perception building.
Download to read more.
You may also be interested in…
Unlocking Insights at PharmaCI: A Recap from Deallus
At Deallus, we constantly strive to immerse ourselves in the latest developments and conversations within the competitive intelligence (CI) landscape. Recently, we had the privilege of attending PharmaCI in Munich, where we engaged in enriching discussions with esteemed clients, peers, and colleagues.
Can AI really help you understand what matters in your market?
The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.
Brain Awareness Week
Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.
Rare Diseases, Pharma’s Perennial Hitmaker
February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.